Poster Presentations 2017
DOI: 10.1136/annrheumdis-2017-eular.2808
|View full text |Cite
|
Sign up to set email alerts
|

SAT0213 Low dose il-2 restores decreased absolute number of regulatory t cells and imbalance between th17 and regulatory t cells in patients with rheumatoid arthritis

Abstract: BackgroundA therapeutic revolution in the past decade is still a considerable unmet need in the treatment of rheumatoid arthritis (RA). On the other hand, dysfunction of regulatory T cells (Tregs) has been considered to be a pivotal cause of RA and correction of this dysfunction to be a potential RA therapy1. However, abnormalities of Tregs in patients with RA were reported controversially in previous studies2, in which only proportion was measured and Tregs were defined using different protein markers.Objecti… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2019
2019
2019
2019

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…In contrast, Tregs actively suppress activation of the immune system and prevent autoimmune disease [7]. Recently, we have reported the reduction of the absolute number of peripheral Tregs but not the increase of effector T and Th17 cells in RA patients [8, 9], which argues and challenges the pathological foundation of conventional immunosuppressive therapy that also nonspecifically inhibits Tregs. Thus, one of goals of a new therapy for RA should be to maintain and restore a relative balance between effector T and Treg cells.…”
Section: Introductionmentioning
confidence: 99%
“…In contrast, Tregs actively suppress activation of the immune system and prevent autoimmune disease [7]. Recently, we have reported the reduction of the absolute number of peripheral Tregs but not the increase of effector T and Th17 cells in RA patients [8, 9], which argues and challenges the pathological foundation of conventional immunosuppressive therapy that also nonspecifically inhibits Tregs. Thus, one of goals of a new therapy for RA should be to maintain and restore a relative balance between effector T and Treg cells.…”
Section: Introductionmentioning
confidence: 99%